Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total

PUBT · 3d ago
Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total
  • Edgewise completed the sale of sevasemten and its muscular dystrophy business to Servier for USD 1.55 billion upfront.
  • Deal includes up to USD 1.1 billion in regulatory and commercial milestones, for total potential consideration of up to USD 2.65 billion.
  • Transaction shifts Edgewise to a cardiovascular focus; proceeds expected to fund EDG-7500 development through potential approval.
  • Phase 3 trial for EDG-7500 in hypertrophic cardiomyopathy expected to start in Q4 2026; Phase 2 for EDG-15400 in HFpEF remains on track.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082902), on July 13, 2026, and is solely responsible for the information contained therein.